Do not self-inject unless trained by a certified medical provider
[23] FDA Safety and Innovation Act of 2012, Pub
43 SeoS-KKwonB
Other notable harms included cardiovascular disorders (13%, 14%, and 11% for semaglutide, liraglutide, and placebo, respectively), injection site reactions (0, 11%, and 6% for semaglutide, liraglutide, and placebo, respectively), and psychiatric disorders (6%, 15%, and 11% for semaglutide, liraglutide, and placebo, respectively)
The weight loss and improvements in metabolic markers seen with oral semaglutide is significant and will positively impact the field of obesity medicine and metabolic conditions, said Sean Wharton